Cancer prevention by targeting angiogenesis
Open Access
- 31 July 2012
- journal article
- review article
- Published by Springer Science and Business Media LLC in Nature Reviews Clinical Oncology
- Vol. 9 (9), 498-509
- https://doi.org/10.1038/nrclinonc.2012.120
Abstract
Healthy individuals can harbour microscopic tumours and dysplastic foci in different organs in an undetectable and asymptomatic state for many years. These lesions do not progress in the absence of angiogenesis or inflammation. Targeting both processes before clinical manifestation can prevent tumour growth and progression. Angioprevention is a chemoprevention approach that interrupts the formation of new blood vessels when tumour cell foci are in an indolent state. Many efficacious chemopreventive drugs function by preventing angiogenesis in the tumour microenvironment. Blocking the vascularization of incipient tumours should maintain a dormancy state such that neoplasia or cancer exist without disease. The current limitations of antiangiogenic cancer therapy may well be related to the use of antiangiogenic agents too late in the disease course. In this Review, we suggest mechanisms and strategies for using antiangiogenesis agents in a safe, preventive clinical angioprevention setting, proposing different levels of clinical angioprevention according to risk, and indicate potential drugs to be employed at these levels. Finally, angioprevention may go well beyond cancer in the prevention of a range of chronic disorders where angiogenesis is crucial, including different forms of inflammatory or autoimmune diseases, ocular disorders, and neurodegeneration.Keywords
This publication has 136 references indexed in Scilit:
- Epigenetic changes induced by curcumin and other natural compoundsGenes & Nutrition, 2011
- Hallmarks of Cancer: The Next GenerationCell, 2011
- Effect of daily aspirin on long-term risk of death due to cancer: analysis of individual patient data from randomised trialsThe Lancet, 2011
- Long-term effect of aspirin on colorectal cancer incidence and mortality: 20-year follow-up of five randomised trialsThe Lancet, 2010
- Regulation of survival, proliferation, invasion, angiogenesis, and metastasis of tumor cells through modulation of inflammatory pathways by nutraceuticalsCancer and Metastasis Reviews, 2010
- Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunityCancer and Metastasis Reviews, 2010
- Role of Nrf2 in prevention of high-fat diet-induced obesity by synthetic triterpenoid CDDO-ImidazolideEuropean Journal of Pharmacology, 2009
- Metabolic regulation and redox activity as mechanisms for angioprevention by dietary phytochemicalsInternational Journal of Cancer, 2009
- Evidence of angiogenic vessels in Alzheimer’s diseaseJournal of Neural Transmission, 2009
- Therapeutic metformin/AMPK activation promotes the angiogenic phenotype in the ERα negative MDA-MB-435 breast cancer modelBreast Cancer Research and Treatment, 2008